{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"0"}]}],"title":"Number of Subjects with Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"}]}],"title":"Number of Events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"description":"Dermatological examinations were performed by the investigator, or at the discretion of the investigator, referred to a dermatologist. The number of participants with non-melanoma skin lessions was assessed from the time of Screening until study completion or discontinuation from the study for any reason.","groups":[{"description":"Participants were randomly assigned to receive oral GSK2118436 150 mg BID. Dose reductions were permitted based on the severity of the hematological toxicity. Stopping recommendations for study treatment were also provided for cases of reoccurring skin toxicity, cardiovascular complication or abnormalities, and liver abnormalities. Participants continued on treatment until DP, death, the occurrence of an unacceptable AE, or withdrawal from the study. Participants who experienced investigator-reported DP but were benefitting from study treatment were permitted to continue GSK2118436 treatment upon approval of the GlaxoSmithKline Medical Monitor.","id":"OG000","title":"GSK2118436 150 mg BID"},{"description":"In the RP, participants received IV DTIC 1000 mg/m\\^2 every 3 weeks. Dose reductions were permitted based on the severity of the hematological toxicity. Stopping recommendations for study treatment were also provided for cases of reoccurring skin toxicity, cardiovascular complication or abnormalities, and liver abnormalities. Participants continued on treatment until DP, death, the occurrence of an unacceptable AE, or withdrawal from the study.","id":"OG001","title":"DTIC 1000 mg/m^2 in RP"}],"paramType":"NUMBER","populationDescription":"Safety Population: all randomized participants who received at least one dose of study drug, based on the actual treatment received, if this differed from that to which the participant was randomized","reportingStatus":"POSTED","timeFrame":"From Screening until study completion or discontinuation from the study (up to 9.9 months)","title":"Number of Participants With Non-melanoma Skin Lesions: Randomized Phase","type":"SECONDARY","unitOfMeasure":"participants"}